title: [Therapeutic monoclonal antibodies against multiple myeloma].
abstract: Multiple myeloma (MM) remains mostly incurable despite the recent progress in the treatment strategy. One of novel fields for anti-MM therapeutic strategy is the development of immunotherapy using monoclonal antibodies (MoAbs) against myeloma-specific antigens. This article focuses on the basic and clinical aspects of several emerging and promising novel MoAbs for MM, such as elotuzumab which targets CS1 and daratumumab which targets CD38. Both antigens are highly expressed in more than 90% of MM patients, and the clinical trials have shown promising anti-MM effects, especially in combination with immunomodulatory agent lenalidomide. We also discuss the characteristics and the results of clinical trials of other MoAbs, such as tabalumab against B cell activating factor or dacetuzumab against CD40, being developed for MM.
authors.forename: Junya
authors.initials: J
authors.lastname: Kuroda
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D053264:B-Cell Activating Factor / Q000276:immunology; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D010455:Peptides / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D053264:B-Cell Activating Factor; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; C076687:CS1 peptide; D051997:ADP-ribosyl Cyclase 1